Wanyi Chen, PhD; Shaan Khurshid, MD, MPH; Daniel E. Singer, MD; et al.
open access
JAMA Health Forum. 2022;3(8):e222419. doi:10.1001/jamahealthforum.2022.2419
This economic evaluation uses a microsimulation decision-analytic model to assess the cost-effectiveness of contemporary atrial fibrillation screening strategies, particularly wrist-worn wearable devices.
Elizabeth M. Stone, MSPH; Kayla N. Tormohlen, PhD, MPH; Alexander D. McCourt, PhD, JD, MPH; et al.
open access
JAMA Health Forum. 2022;3(8):e222461. doi:10.1001/jamahealthforum.2022.2461
This cross-sectional study assesses the association between state laws limiting the dose and/or duration of opioid prescriptions and the receipt of opioid prescriptions among children and adolescents in the US.
Maricruz Rivera-Hernandez, PhD; Daeho Kim, PhD; Kevin H. Nguyen, PhD; et al.
open access
has audio
JAMA Health Forum. 2022;3(8):e222534. doi:10.1001/jamahealthforum.2022.2534
This cross-sectional study of patients with kidney failure in Puerto Rico examines dialysis care, migration, and mortality rates before, during, and after Hurricane Maria.
-
Podcast:
Migration and Mortality Among Patients With Kidney Failure After Hurricane Maria in Puerto Rico
Matthew D. Eisenberg, PhD; Yashaswini Singh, MPA; Neeraj Sood, PhD
open access
JAMA Health Forum. 2022;3(8):e222570. doi:10.1001/jamahealthforum.2022.2570
This cross-sectional study provides evidence on the association of direct-to-consumer-advertising of prescription drugs with consumer health-related intentions and beliefs among individuals at risk of cardiovascular disease.
Evan D. Peet, PhD; David Powell, PhD; Rosalie Liccardo Pacula, PhD
open access
JAMA Health Forum. 2022;3(8):e222663. doi:10.1001/jamahealthforum.2022.2663
This observational study assesses trends in out-of-pocket costs for naloxone in the US between 2010 and 2018 and examines variation by drug brand and payer.
Kerstin N. Vokinger, MD, JD, PhD, LLM; Aaron S. Kesselheim, MD, JD, MPH; Camille E. G. Glaus, BSc, JD, LLM; et al.
open access
JAMA Health Forum. 2022;3(8):e222685. doi:10.1001/jamahealthforum.2022.2685
This cohort study assesses the therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and European Union from 2007 to 2021.
Samantha G. Auty, MS; Megan B. Cole, PhD, MPH; Jacob Wallace, PhD
open access
JAMA Health Forum. 2022;3(8):e222812. doi:10.1001/jamahealthforum.2022.2812
This cross-sectional study of data from the Treatment Episode Data Set鈥擜dmissions examines the association between changes in Medicaid coverage of substance use services and admissions for substance use treatment in Maryland and Nebraska.
Amelia M. Haviland, PhD; Sai Ma, PhD; David J. Klein, MS; et al.
open access
JAMA Health Forum. 2022;3(8):e222826. doi:10.1001/jamahealthforum.2022.2826
This population-based cross-sectional study measures the extent to which Medicare Advantage enrollees experience higher quality of care and have better patient experiences in higher-premium plans.